Our exploratory analysis initially showed a trend towards a decrease in the mean number of clinically significant exacerbations for patients with high eosinophilic count (≥ 300 cells/μl), but it was not statistically significant due to the small subset of available data.
← all excerpts
Real-world effectiveness of omalizumab for severe allergic asthma treatment in Colombia.
1
—
—